NESS ZIONA, Israel, January 2,
2017 /PRNewswire/ --
Investor Shares BiondVax Vision of Commercializing
World's First Universal Flu Vaccine
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV)
is honored to announce that Angels High Tech Investments Ltd. has
agreed to invest NIS 10.9 million,
approximately $US 2.83 million, in
exchange for 33.8 million ordinary BiondVax shares on the Tel Aviv
Stock Exchange (equivalent to 844,000 NASDAQ listed ADS) at the
December 29, 2016 Tel Aviv closing
market price. Following the transaction, Angels Investments will
hold 19.99% of all issued and outstanding share capital of the
Company.
Angels Investments is a company fully owned by Marius Nacht, Co-founder and Chairman of Check
Point (NASDAQ: CHKP). Angels' healthcare and life science portfolio
is managed by aMoon Partners which is co-led by Dr. Yair Schindel and Marius
Nacht.
Ron Babecoff, BiondVax's Founder, President and CEO
noted, "This investment is a vote of confidence in BiondVax and its
universal influenza vaccine candidate. We are now better positioned
to complete our development plans and commercialize our vaccine
worldwide. This strategic partnership, together with clinical
results and ongoing clinical trial collaborations in Europe and the US (NIH) will enable us to
proceed confidently into Phase 3 as planned."
Dr. Yair Schindel, aMoon
Partners' Co-founder and Managing Partner commented, "We
see great potential in BiondVax's universal flu vaccine. We
expect that this investment is the beginning of a strong
partnership with BiondVax and we look forward to doing our part in
helping reduce the global morbidity and mortality caused by
influenza viruses."
About BiondVax Pharmaceuticals Ltd
BiondVax is a clinical phase biopharmaceutical company
developing a universal flu vaccine. The vaccine is designed to
provide multi-season protection against most seasonal and pandemic
human influenza virus strains. BiondVax's proprietary technology
utilizes a unique combination of conserved and common peptides from
influenza virus proteins, activating both arms of the immune system
for a cross-protecting and long-lasting effect. BiondVax is traded
on NASDAQ: BVXV and TASE: BVXV. Please visit
http://www.biondvax.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend,"
"plan," "continue," "may," "will," "anticipate," and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements involve certain risks
and uncertainties reflect the management's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause the
results to differ materially from those expected by the management
of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include,
but are not limited to, the risk that drug development involves a
lengthy and expensive process with uncertain outcome, the results
of the current Phase 2
& contemplated phase 3 trials, the
adequacy of available cash resources to fund product
development and commercialization and the ability to
raise capital when needed. The risks, uncertainties and assumptions
referred to above are discussed in detail in our reports filed with
the Securities and Exchange Commission, including
our annual report for the year
ended December 31,
2015 on Form 20-F filed with the Securities and
Exchange Commission on April 27,
2016. BiondVax Pharmaceuticals Ltd. undertakes no obligation
to update or revise any forward-looking
statements.
For further information, please contact:
Joshua E Phillipson
Business Development
+972-8-930-2529 x5105
j.phillipson@biondvax.com
Kenny Green
Investor Relations
+1-646-201-9246
kenny@biondvax.com
SOURCE BiondVax Pharmaceuticals Ltd.